All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Dr Husain on Developments in ALK+ NSCLC

July 29th 2023

Hatim Husain, MD, discusses developments in ALK-positive non–small cell lung cancer.

Lung Cancer Trials Require Modified Eligibility Criteria to Better Reflect Real-World Population

July 28th 2023

Edward S. Kim, MD, MBA, discusses necessary changes that would make cancer research more accessible to patients in community settings, multidisciplinary efforts that should take place at every step of the trial design and implementation process, and how future clinical trials should be intentional about the patient demographics.

Tackling Resistance Mechanisms Is the Next Step in Immunotherapy Development for NSCLC

July 28th 2023

Immunotherapy administered alone or in combination with chemotherapy has become the standard of care across advanced non–small cell lung cancer in several settings, with continued effort devoted to further enhancing and improving upon these treatments.

Neoadjuvant Pembrolizumab Plus Chemotherapy Improves pCR Rate in High-Risk, Early-Stage ER+/HER2– Breast Cancer

July 28th 2023

Neoadjuvant pembrolizumab plus chemotherapy led to an improvement in pathological complete response rate compared with chemotherapy plus placebo in patients with high-risk, early-stage, estrogen receptor–positive, HER2-negative breast cancer.

Sacituzumab Govitecan Wins Approval in Europe for Pretreated HR+/HER2– Metastatic Breast Cancer

July 28th 2023

The European Commission has approved sacituzumab govitecan-hziy for the treatment of adult patients with unresectable or metastatic hormone receptor–positive, HER2-negative breast cancer who have received endocrine-based therapy and at least 2 additional systemic therapies in the advanced setting

Investigators Set Sights on Novel Agents Following Negative Studies in Relapsed Small Cell Lung Cancer

July 28th 2023

New agents in development including ABBV-011 and BL-B01D1 seek to turn the tides of relapsed extensive-stage small cell lung cancer; although chemoimmunotherapy has earned its right as the frontline standard of care, both classes of agents have yet to demonstrate benefit in second or later lines.

Uproleselan Plus SOC Targeted Regimens and Chemotherapy Under Investigation in AML

July 28th 2023

Bhavana “Tina” Bhatnagar, DO, discusses the mechanism of action of uproleselan, the potential efficacy and safety benefits of adding this agent to standard therapeutic regimens in patients with AML, and the importance of considering MRD negativity as an end point in AML clinical trials.

UAB Plays Major Role in Launching Statewide Action Plan to Eliminate Cervical Cancer

July 28th 2023

The University of Alabama at Birmingham, in partnership with the Alabama Department of Public Health and the American Cancer Society, recently launched Wipe Out Cervical Cancer — a statewide action plan to eliminate cervical cancer as a public health problem in Alabama.

Long-Term Data Show Improved CR Rates for Cosibelimab in Advanced CSCC

July 28th 2023

Long-term data demonstrated that treatment with cosibelimab improved complete response rates over time in patients with locally advanced or metastatic cutaneous squamous cell carcinoma in a phase 1 trial.

EU Approves Piflufolastat (18F) PSMA PET Imaging Agent for Prostate Cancer

July 28th 2023

The European Commission has approved piflufolastat (18F) for the detection of prostate-specific membrane antigen–positive lesions with positron emission tomography in adults with prostate cancer.

Neighborhood Plays an Important Role in Clinical Outcomes for Patients With Breast Cancer

July 28th 2023

Addressing socioeconomic health disparities has been a crucial objective of health policy in the United States. The relationship between cancer incidence and mortality and socioeconomic status varies across malignancies.

Perioperative Nivolumab Plus Chemo Improves pCR, Survival in Stage III NSCLC

July 28th 2023

Neoadjuvant treatment with nivolumab plus platinum-based chemotherapy followed by adjuvant nivolumab increased pathological complete response rates and prolonged survival compared with neoadjuvant chemotherapy alone in patients with resectable stage IIIA/B non–small cell lung cancer.

Perioperative Immunotherapy Improves EFS, But Clouds Optimal Sequencing in Early NSCLC

July 27th 2023

Positive event-free survival data from the phase 3 AEGEAN, NEOTORCH, and KEYNOTE-671 trials add further evidence to the benefit of perioperative immunotherapy in early-stage non–small cell lung cancer but have yet to show clear biomarkers of response beyond PD-L1.

OS Data Reinforce Adjuvant Osimertinib as Standard of Care for Resectable EGFR+ NSCLC

July 27th 2023

Overall survival analysis from ADAURA bolsters the already impressive disease-free survival data for patients with EGFR-mutant non–small cell lung cancer.

Phase 2 Data Indicate Role of Tovorafenib in Pediatric Low-Grade Glioma

July 27th 2023

Sarah E. S. Leary, MD, MS, spotlights the importance of developing effective treatments for pediatric patients with low-grade glioma, key findings with tovorafenib in patients with RAF mutations, and how this agent may influence the low-grade glioma therapeutic landscape going forward.

Continued Emergence of Targeted Therapies for EGFR+ NSCLC Underscores Importance of Molecular Testing

July 27th 2023

Pasi A. Jänne, MD, PhD, details common EGFR mutations in NSCLC, the importance of testing for EGFR mutations in all patients, the clinical implications of overall survival data for adjuvant osimertinib from the ADAURA trial, and ongoing trials examining combination therapies to potentially improve upon the use of single-agent osimertinib.

Chemotherapy Drug Shortages Affecting Cancer Patients in Florida, Across the Country

July 27th 2023

The platinum drugs, carboplatin and cisplatin, known for effectively treating lung, head and neck, breast, ovarian, gastric, bladder and testicular cancers, have been in short order for the past few months.

UGN-102 Improves Survival, Elicits CRs in Low-Grade, Intermediate-Risk NMIBC

July 27th 2023

Treatment with UGN-102 with or without transurethral resection of bladder tumors led to an improvement in disease-free survival compared with TURBT alone in patients with low-grade, intermediate-risk non–muscle-invasive bladder cancer.

Upifitamab Rilsodotin Fails to Meet ORR End Point in NaPi2b+ Platinum-Resistant Ovarian Cancer

July 27th 2023

The phase 1/2 UPLIFT trial evaluating the antibody-drug conjugate upifitamab rilsodotin in patients with platinum-resistant ovarian cancer failed to meet its primary end point of investigator-assessed overall response rate in the NaPi2b-positive population.

Novel Program Provides Avenue for Increased Biosimilar Uptake, Reduced Cost

July 27th 2023

The implementation of a pharmacist-driven biosimilar substitution program across American Oncology Network institutions resulted in increased uptake of biosimilar agents as well as financial savings for payers, patients, and providers.